On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

Sep. 25, 2024 — Almost everyone knows about HIV. Fewer people know about its relative, HTLV-1. However, HTLV-1 can cause serious illnesses, including cancer. To develop ways to combat this virus ...

This is a news collection page for Darwin. Check this page for latest news headlines covering major stories, events from Darwin and surrounding Northern Territory. Get breaking news faster than ...

We recently compiled a list of the 10 Buzzing AI Health Stocks. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other buzzing AI health stocks. The ...

We recently compiled a list of the 10 Buzzing AI Health Stocks. In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against the other buzzing AI health stocks.

Amgen Inc. avoided Regeneron Pharmaceuticals Inc.’s attempt ... of US Patent No. 11,084,865 require that the vascular endothelial growth factor antagonist—aflibercept, Eylea’s active ingredient—and ...

Myopia was less common and less severe in patients who received aflibercept than in patients who received laser photocoagulation, a study shows. shows sustained efficacy and safety at 3 years of age, ...

Roughly a year and a half after the introduction of a shareholder lawsuit, Amgen has lost its bid to toss the case accusing the California biotech giant of concealing a massive tax bill with the IRS.

A 0.4 mg dose of aflibercept in infancy to treat retinopathy of prematurity (ROP) shows sustained efficacy and safety at 3 years of age, according to research presented at EURETINA 2024.

Patients with diabetic macular edema can expect similar BCVA improvements and CST reductions using an aflibercept biosimilar compared with conventional aflibercept. An aflibercept biosimilar is ...